Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript Summary
Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript Summary
Gross margin was 55.8% for the quarter, impacted by onetime adjustments; however, excluding these, the adjusted gross margin was 59.7%.The following is a summary of the Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript:
以下是Exagen公司（XGN）2024年第三季度業績會議電話交易摘要:
Financial Performance:
財務表現：
Third quarter revenue reached $12.5 million despite a $1.2 million net negative impact from one-time adjustments.
Adjusted EBITDA loss was approximately $4 million for the quarter, on track for a 30% improvement for the full year.
Gross margin was 55.8% for the quarter, impacted by onetime adjustments; however, excluding these, the adjusted gross margin was 59.7%.
第三季度營業收入達到1250萬美元，儘管一次性調整影響淨額爲120萬美元。
調整後的季度EBITDA虧損約爲400萬美元，全年將實現30%的改善。
本季度毛利率爲55.8%，受一次性調整影響；然而，排除這些因素，調整後的毛利率爲59.7%。
Business Progress:
業務進展：
Exagen is nearing the commercial launch of new biomarker products through the AVISE CTD platform, expecting significant gains in ASP and margin expansion.
A strong focus has been placed on refining commercial strategies and marketing for the impending launch of new biomarker assays.
Exagen即將通過AVISE CTD平台推出新生物標誌物產品，預計ASP和毛利率將顯著提高。
已經大力優化商業戰略和新生物標誌物檢測產品的營銷工作，以應對即將推出的新產品。
Opportunities:
機會：
The upcoming new proprietary biomarkers are anticipated to drive increased ASP and market demand, aligning with innovation and expanding market opportunities.
Enhanced marketing campaigns and educational initiatives are lined up to support the commercial launch of new test products.
未來即將推出的新專有生物標誌物有望推動平均銷售價格和市場需求增加，符合創新並擴大市場機會。
加強營銷活動和教育計劃，以支持新測試產品的商業推出。
Risks:
風險：
Seasonal factors and weather-related events impacted testing volumes and could pose continued operational risks.
The $1.2 million in one-time adjustments to revenue due to a self-corrected CPT coding discrepancy and at-risk accounts receivable signify potential financial and operational vulnerabilities.
季節因素和天氣相關事件影響了測試量，可能會帶來持續的運營風險。
由於自我糾正的CPt編碼差錯和有風險的應收賬款，導致營業收入產生了120萬美元的一次性調整，標誌着潛在的財務和運營風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
